Geode Capital Management LLC Has $207.54 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Geode Capital Management LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 0.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,706,353 shares of the biotechnology company's stock after purchasing an additional 9,999 shares during the quarter. Geode Capital Management LLC owned approximately 1.79% of Sarepta Therapeutics worth $207,538,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of SRPT. Manchester Capital Management LLC raised its holdings in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB increased its stake in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. increased its stake in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 232 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth about $36,000. Finally, Steward Partners Investment Advisory LLC boosted its stake in Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 194 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

SRPT has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. HC Wainwright raised shares of Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 price target for the company in a report on Wednesday, April 2nd. Scotiabank dropped their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a report on Thursday, March 20th. Finally, Morgan Stanley cut their price objective on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a research report on Friday. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $161.83.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Price Performance

Shares of SRPT traded up $0.72 on Friday, hitting $51.03. The company's stock had a trading volume of 4,036,516 shares, compared to its average volume of 1,385,946. The company has a 50 day moving average price of $88.11 and a 200 day moving average price of $110.20. Sarepta Therapeutics, Inc. has a fifty-two week low of $48.01 and a fifty-two week high of $173.25. The company has a market capitalization of $4.95 billion, a PE ratio of 40.82 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.